370 related articles for article (PubMed ID: 28881511)
1. [Role of IgG antibody to galactose-deficient IgA1 in children with IgA nephropathy].
Zhou N; Zhang H; Liu XR; Sun Q; Meng Q; Chen Z; Shen Y
Zhonghua Er Ke Za Zhi; 2017 Sep; 55(9):663-667. PubMed ID: 28881511
[No Abstract] [Full Text] [Related]
2. Clinical Significance of Serum Galactose-Deficient IgA1 Level in Children with IgA Nephropathy.
Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Ohta K; Yachie A
J Immunol Res; 2020; 2020():4284379. PubMed ID: 32537466
[TBL] [Abstract][Full Text] [Related]
3. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.
Yanagawa H; Suzuki H; Suzuki Y; Kiryluk K; Gharavi AG; Matsuoka K; Makita Y; Julian BA; Novak J; Tomino Y
PLoS One; 2014; 9(5):e98081. PubMed ID: 24858067
[TBL] [Abstract][Full Text] [Related]
4. A pilot and comparative study between pathological and serological levels of immunoglobulin and complement among three kinds of primary glomerulonephritis.
Dong J; Peng T; Gao J; Jia X; Yan G; Wang Y
BMC Immunol; 2018 Jun; 19(1):18. PubMed ID: 29925312
[TBL] [Abstract][Full Text] [Related]
5. Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
Suzuki H; Allegri L; Suzuki Y; Hall S; Moldoveanu Z; Wyatt RJ; Novak J; Julian BA
Dis Markers; 2016; 2016():7806438. PubMed ID: 27647947
[TBL] [Abstract][Full Text] [Related]
6. The glycans deficiencies of macromolecular IgA1 is a contributory factor of variable pathological phenotypes of IgA nephropathy.
Xu LX; Yan Y; Zhang JJ; Zhang Y; Zhao MH
Clin Exp Immunol; 2005 Dec; 142(3):569-75. PubMed ID: 16297170
[TBL] [Abstract][Full Text] [Related]
7. Serum GDIgA1 levels in children with IgA nephropathy and Henoch-Schönlein nephritis.
Mizerska-Wasiak M; Gajewski Ł; Cichoń-Kawa K; Małdyk J; Dziedzic-Jankowska K; Leszczyńska B; Rybi-Szumińska A; Wasilewska A; Pukajło-Marczyk A; Zwolińska D; Bieniaś B; Sikora P; Szczepańska M; Stelmaszczyk-Emmel A; Górska E; Pańczyk-Tomaszewska M
Cent Eur J Immunol; 2018; 43(2):162-167. PubMed ID: 30135628
[TBL] [Abstract][Full Text] [Related]
8. Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.
Liu Y; Li H; Yu H; Wang F; Jia J; Yan T
BMC Nephrol; 2022 Jan; 23(1):25. PubMed ID: 35016642
[TBL] [Abstract][Full Text] [Related]
9. Serum galactose-deficient IgA1 levels in children with IgA nephropathy.
Jiang M; Jiang X; Rong L; Xu Y; Chen L; Qiu Z; Mo Y
Int J Clin Exp Med; 2015; 8(5):7861-6. PubMed ID: 26221341
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy.
Wada Y; Matsumoto K; Suzuki T; Saito T; Kanazawa N; Tachibana S; Iseri K; Sugiyama M; Iyoda M; Shibata T
PLoS One; 2018; 13(11):e0206865. PubMed ID: 30388165
[TBL] [Abstract][Full Text] [Related]
11. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.
Berthelot L; Robert T; Vuiblet V; Tabary T; Braconnier A; Dramé M; Toupance O; Rieu P; Monteiro RC; Touré F
Kidney Int; 2015 Oct; 88(4):815-22. PubMed ID: 26061544
[TBL] [Abstract][Full Text] [Related]
12. Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.
Rizk DV; Saha MK; Hall S; Novak L; Brown R; Huang ZQ; Fatima H; Julian BA; Novak J
J Am Soc Nephrol; 2019 Oct; 30(10):2017-2026. PubMed ID: 31444275
[TBL] [Abstract][Full Text] [Related]
13. Self-aggregated deglycosylated IgA1 with or without IgG were associated with the development of IgA nephropathy.
Yan Y; Xu LX; Zhang JJ; Zhang Y; Zhao MH
Clin Exp Immunol; 2006 Apr; 144(1):17-24. PubMed ID: 16542360
[TBL] [Abstract][Full Text] [Related]
14. Immune Characteristics of IgA Nephropathy With Minimal Change Disease.
Li H; Lu W; Li H; Liu X; Zhang X; Xie L; Lan P; Yu X; Dai Y; Xie X; Lv J
Front Pharmacol; 2021; 12():793511. PubMed ID: 34975488
[No Abstract] [Full Text] [Related]
15. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy.
Nakata J; Suzuki Y; Suzuki H; Sato D; Kano T; Yanagawa H; Matsuzaki K; Horikoshi S; Novak J; Tomino Y
PLoS One; 2014; 9(2):e89707. PubMed ID: 24586974
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.
Zhang K; Li Q; Zhang Y; Shang W; Wei L; Li H; Gao S; Yan T; Jia J; Liu Y; Lin S
Kidney Blood Press Res; 2019; 44(5):1196-1206. PubMed ID: 31574506
[TBL] [Abstract][Full Text] [Related]
17. Activation of the interleukin-4/signal transducer and activator of transcription 6 signaling pathway and homeodomain-interacting protein kinase 2 production by tonsillar mononuclear cells in IgA nephropathy.
He L; Peng Y; Liu H; Yin W; Chen X; Peng X; Shao J; Liu Y; Liu F
Am J Nephrol; 2013; 38(4):321-32. PubMed ID: 24107646
[TBL] [Abstract][Full Text] [Related]
18. Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study.
Bagchi S; Lingaiah R; Mani K; Barwad A; Singh G; Balooni V; Bhowmik D; Agarwal SK
PLoS One; 2019; 14(3):e0214256. PubMed ID: 30917188
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.
Zhao YF; Zhu L; Liu LJ; Shi SF; Lv JC; Zhang H
BMC Nephrol; 2017 Sep; 18(1):301. PubMed ID: 28969604
[TBL] [Abstract][Full Text] [Related]
20. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.
Suzuki H; Fan R; Zhang Z; Brown R; Hall S; Julian BA; Chatham WW; Suzuki Y; Wyatt RJ; Moldoveanu Z; Lee JY; Robinson J; Tomana M; Tomino Y; Mestecky J; Novak J
J Clin Invest; 2009 Jun; 119(6):1668-77. PubMed ID: 19478457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
